The Ideal Thrombolytic Agent: GISSI‐2 and ISIS‐3

ALDO PIETRO MAGGIONI, CLAUDIO FRESCO, MARIA GRAZIA FRANZOSI, GIANNI TOGNONI, GISSI‐2 INVESTIGATORS

Research output: Contribution to journalArticlepeer-review

Abstract

Streptokinase (SK) and tissue plasminogen activator (alteplase [tPA]) are by far the most intensively studied thrombolytic agents, but only recently a direct head‐to‐head comparison (GISSI‐2 Trial, in which 12,490 patients have been randomized) has become available to the scientific community. This trial, with its international extension (the International tPA/SK Mortality Trial) recruited more than 20,000 patients, showed that the two drugs tested (SK and tPA) were substantially comparable as far as the clinical events were considered. ISIS‐3, the largest randomized clinical trial ever performed, compares SK, tPA, and APSAC in a factorial design. Its results will be available before spring, 1991. It is likely that these two studies, if the results will be consistent, will give a definitive answer about comparison among thrombolytic drugs. As a consequence of that achievement, the interest of the scientific community will possibly be directed towards the long‐term prevention of the infarct complications, namely ventricular remodeling and infarct expansion or life‐threatening arrhythmias.

Original languageEnglish
Pages (from-to)157-168
Number of pages12
JournalJournal of Interventional Cardiology
Volume3
Issue number3
DOIs
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'The Ideal Thrombolytic Agent: GISSI‐2 and ISIS‐3'. Together they form a unique fingerprint.

Cite this